Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus

An Anonymized, De-identified Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus

This observational study is designed to assess the effects of Envlo Tablet or Envlomet SR Tablet on weight loss and safety in patients with Type 2 diabetes, conducted in real primary care settings over a period of 24 weeks.

Study Overview

• Status: Active, not recruiting
• Conditions: Type 2 Diabetes Mellitus
• Intervention / Treatment: Drug: Envlo Tablet; Drug: Envolomet SR Tablet

Detailed Description

The study plans to recruit patients with Type 2 diabetes who are scheduled to receive Envlo Tablet or Envlomet SR Tablet based on the attending physician's medical judgment, regardless of previous diabetes treatment. However, voluntary consent from patients is required for participation in the study, even if Envlo Tablet or Envlomet SR Tablet are prescribed.

Data collection will occur for up to 24 weeks post-Envlo Tablet or Envlomet SR Tablet initiation, capturing demographic information, physical measurements, vital signs, and lifestyle factors. Follow-up visits at 12 weeks and 24 weeks post-baseline will be conducted to collect data, including clinical indicators, safety evaluations, and adverse events. Data will be collected based on routine clinical records, with no mandatory study-specific visits or interventions.

Overall, this observational study aims to collect data on demographics, physical measurements, vital signs, and clinical indicators in patients receiving Envlo Tablet or Envlomet SR Tablet in real-world clinical settings, utilizing information obtained during routine patient care processes.

• Study Type: Observational
• Enrollment (Actual): 200

Contacts and Locations

Study Locations

• South Korea
  • Seoul, South Korea
    • Kyung Hee University Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

The mean and standard deviation of the change from baseline to 12 or 24 weeks in weight and body mass index (BMI) from previously conducted Phase 2 and Phase 3 clinical trials were used as references for calculation using G*Power 3.1.9.7.

Description

Inclusion Criteria:

1. Adults aged 19 to 80 years.

2. Patients with Type 2 diabetes who are scheduled to receive initial treatment with Enavogliflozin or Enavogliflozin Extended-Release Tablets based on the attending physician's medical judgment, within the following insurance coverage ranges:

   • Enavogliflozin monotherapy
   • Combination therapy of Enavogliflozin with two agents (metformin)
   • Combination therapy of Enavogliflozin with three agents (metformin + DPP-4 inhibitor)

3. Patients with obesity beyond the pre-obesity stage according to the 2022 Korean Endocrine Society obesity treatment guidelines:

   • Pre-obesity stage: BMI 23~24.9 kg/m2
   • Stage 1 obesity: BMI 25~29.9 kg/m2
   • Stage 2 obesity: BMI 30~34.9 kg/m2
   • Stage 3 obesity: BMI ≥ 35 kg/m2
4. Individuals planning to undertake appropriate exercise and dietary therapy for glycemic control during the observational study period.
5. Fertile women and men who agree to contraception according to appropriate contraceptive methods during the observational study period or have no plans for pregnancy, adhering to methods such as hormonal contraceptives, intrauterine devices or systems, tubal ligation, vasectomy, dual contraception methods (such as cervical cap and male condom), etc.
6. Individuals who have received detailed explanation and have understood the nature of the observational study and the investigational drug, and have provided written consent to participate voluntarily in the observational study and to comply with subject precautions during the study period.

Exclusion Criteria:

1. Individuals with diabetes other than Type 2 diabetes (Type 1 diabetes, diabetic ketoacidosis, gestational diabetes, etc.).

2. Individuals contraindicated for Enavogliflozin or Enavogliflozin Extended-Release Tablets based on the approved indications:

   • Patients with a history of hypersensitivity reactions to the components of Enavogliflozin or Enavogliflozin Extended-Release Tablets
   • Patients with an eGFR (estimated Glomerular Filtration Rate) less than 30 mL/min/1.73m2, end-stage renal disease, or undergoing dialysis
   • Patients with moderate to severe hepatic impairment (AST or ALT > 3 times the upper limit of normal, Total Bilirubin > 2 times the upper limit of normal, hepatitis or hepatic failure)
   • Patients classified as NYHA (New York Heart Association) class III or IV
3. Patients initiating treatment with Enavogliflozin or Enavogliflozin Extended-Release Tablets at enrollment with an eGFR of less than 60 mL/min/1.73m2.
4. Patients with unstable weight due to treatment with obesity drugs or weight loss medications within 3 months prior to enrollment or other treatments (surgery, dietary therapy, etc.).
5. Individuals with diminished mental capacity.
6. Pregnant and lactating women.
7. Individuals currently participating in another clinical trial and receiving investigational drugs or investigational medical devices.
8. Other individuals deemed unsuitable for participation in the observational study based on the investigator's (attending physician's) judgment.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
patient diagnosed with type2 diabetes mellitus	Drug: Envlo Tablet; Enavogliflozin 0.3mg; Drug: Envolomet SR Tablet; Enavogliflozin 0.3mg/Metformin1,000mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
change in BMI	change in BMI at 24 weeks from baseline	24 weeks
change in body weight	change in body weight at 24 weeks from baseline	24 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
change in BMI	change in BMI at 12 weeks from baseline	12 weeks
change in body weight	change in body weight at 12 weeks from baseline	12 weeks
Proportion of subjects achieving ≥ 5% reduction in BMI	Proportion of subjects achieving ≥ 5% reduction in BMI at 12 weeks compared to baseline	12 weeks
Proportion of subjects achieving ≥ 5% reduction in BMI	Proportion of subjects achieving ≥ 5% reduction in BMI at 24 weeks compared to baseline	24 weeks
Proportion of subjects achieving ≥ 5% reduction in weight	Proportion of subjects achieving ≥ 5% reduction in weight at 12 weeks compared to baseline	12 weeks
Proportion of subjects achieving ≥ 5% reduction in weight	Proportion of subjects achieving ≥ 5% reduction in weight at 24 weeks compared to baseline	24 weeks
Change in body composition analyzer indicators (body fat mass, visceral fat mass, muscle mass, waist/hip circumference, etc.)	Change in body composition analyzer indicators (body fat mass, visceral fat mass, muscle mass, waist/hip circumference, etc.) at 12 weeks compared to baseline	12 weeks
Change in body composition analyzer indicators (body fat mass, visceral fat mass, muscle mass, waist/hip circumference, etc.)	Change in body composition analyzer indicators (body fat mass, visceral fat mass, muscle mass, waist/hip circumference, etc.) at 24 weeks compared to baseline	24 weeks
Change in HbA1c	Change in HbA1c at 12 weeks compared to baseline	12 weeks
Change in HbA1c	Change in HbA1c at 24 weeks compared to baseline	24 weeks
Change in FPG	Change in FPG at 12 weeks compared to baseline	12 weeks
Change in FPG	Change in FPG at 24 weeks compared to baseline	24 weeks
Proportion of subjects achieving HbA1c < 7%	Proportion of subjects achieving HbA1c < 7% at 12 weeks compared to baseline	12 weeks
Proportion of subjects achieving HbA1c < 7%	Proportion of subjects achieving HbA1c < 7% at 24 weeks compared to baseline	24 weeks
Proportion of subjects achieving HbA1c < 6.5%	Proportion of subjects achieving HbA1c < 6.5% at 12 weeks compared to baseline	12 weeks
Proportion of subjects achieving HbA1c < 6.5%	Proportion of subjects achieving HbA1c < 6.5% at 24 weeks compared to baseline	24 week
Proportion of subjects achieving therapeutic response [change in HbA1c (baseline HbA1c - HbA1c at each evaluation time point) > 0.5% or HbA1c < 7%]	Proportion of subjects achieving therapeutic response [change in HbA1c (baseline HbA1c - HbA1c at each evaluation time point) > 0.5% or HbA1c < 7%] at 12 weeks compared to baseline	12 weeks
Proportion of subjects achieving therapeutic response [change in HbA1c (baseline HbA1c - HbA1c at each evaluation time point) > 0.5% or HbA1c < 7%]	Proportion of subjects achieving therapeutic response [change in HbA1c (baseline HbA1c - HbA1c at each evaluation time point) > 0.5% or HbA1c < 7%] at 24 weeks compared to baseline	24 weeks

Collaborators and Investigators

• Sponsor: Daewoong Pharmaceutical Co. LTD.

Study record dates

Study Major Dates

• Study Start (Actual): June 11, 2024
• Primary Completion (Estimated): December 31, 2025
• Study Completion (Estimated): June 30, 2026

Study Registration Dates

• First Submitted: May 14, 2024
• First Submitted That Met QC Criteria: May 21, 2024
• First Posted (Actual): May 23, 2024

Study Record Updates

• Last Update Posted (Estimated): September 2, 2025
• Last Update Submitted That Met QC Criteria: August 28, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Nutritional and Metabolic Diseases; Diabetes Mellitus, Type 2
• Other Study ID Numbers: DW_ODNENV_DB_02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No